MDGL

MDGL

USD

Madrigal Pharmaceuticals Inc. Common Stock

$489.260+1.230 (0.252%)

Real-time Price

Healthcare
Biotechnology
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$488.030

High

$494.550

Low

$477.000

Volume

0.76M

Company Fundamentals

Market Cap

11.1B

Industry

Biotechnology

Country

United States

Trading Stats

Avg Volume

0.37M

Exchange

NMS

Currency

USD

52-Week Range

Low $265Current $489.260High $496.98

Related News

Analyst Upgrades

B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445

B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals from Underperform to Neutral and raises the price target from $266 to $445.

View more
B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445
GlobeNewswire

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the

View more
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025
GlobeNewswire

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated

View more
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrades

Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580

Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals with a Buy rating and announces Price Target of $580.

View more
Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580